CYP19A1 mediates severe SARS-CoV-2 disease outcome in males

Stephanie Stanelle-Bertram,Sebastian Beck,Nancy Kouassi Mounogou,Berfin Schaumburg,Fabian Stoll,Amirah Al Jawazneh,Zoé Schmal,Tian Bai,Martin Zickler,Georg Beythien,Kathrin Becker,Madeleine de la Roi,Fabian Heinrich,Claudia Schulz,Martina Sauter,Susanne Krasemann,Philine Lange,Axel Heinemann,Debby van Riel,Lonneke Leijten,Lisa Bauer,Thierry P P van den Bosch,Boaz Lopuhaä,Tobias Busche,Daniel Wibberg,Dirk Schaudien,Torsten Goldmann,Anna Lüttjohann,Jenny Ruschinski,Hanna Jania,Zacharias Müller,Vinicius Pinho Dos Reis,Vanessa Krupp-Buzimkic,Martin Wolff,Chiara Fallerini,Margherita Baldassarri,Simone Furini,Katrina Norwood,Christopher Käufer,Nina Schützenmeister,Maren von Köckritz-Blickwede,Maria Schroeder,Dominik Jarczak,Axel Nierhaus,Tobias Welte,Stefan Kluge,Alice C McHardy,Frank Sommer,Jörn Kalinowski,Susanne Krauss-Etschmann,Franziska Richter,Jan von der Thüsen,Wolfgang Baumgärtner,Karin Klingel,Benjamin Ondruschka,GEN-COVID Multicenter Study Group,Alessandra Renieri,Gülsah Gabriel

DOI: https://doi.org/10.1016/j.xcrm.2023.101152

2023-09-19

Abstract:Male sex represents one of the major risk factors for severe COVID-19 outcome. However, underlying mechanisms that mediate sex-dependent disease outcome are as yet unknown. Here, we identify the CYP19A1 gene encoding for the testosterone-to-estradiol metabolizing enzyme CYP19A1 (also known as aromatase) as a host factor that contributes to worsened disease outcome in SARS-CoV-2-infected males. We analyzed exome sequencing data obtained from a human COVID-19 cohort (n = 2,866) using a machine-learning approach and identify a CYP19A1-activity-increasing mutation to be associated with the development of severe disease in men but not women. We further analyzed human autopsy-derived lungs (n = 86) and detect increased pulmonary CYP19A1 expression at the time point of death in men compared with women. In the golden hamster model, we show that SARS-CoV-2 infection causes increased CYP19A1 expression in the lung that is associated with dysregulated plasma sex hormone levels and reduced long-term pulmonary function in males but not females. Treatment of SARS-CoV-2-infected hamsters with a clinically approved CYP19A1 inhibitor (letrozole) improves impaired lung function and supports recovery of imbalanced sex hormones specifically in males. Our study identifies CYP19A1 as a contributor to sex-specific SARS-CoV-2 disease outcome in males. Furthermore, inhibition of CYP19A1 by the clinically approved drug letrozole may furnish a new therapeutic strategy for individualized patient management and treatment.